File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Safety and tolerance of high intensive focused ultrasound ablation for hepatocellular carcinoma in 100 consecutive patients

TitleSafety and tolerance of high intensive focused ultrasound ablation for hepatocellular carcinoma in 100 consecutive patients
Authors
KeywordsMedical sciences
Endocrinology
Issue Date2011
PublisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
Citation
The 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 453-454, abstract PP33-13 How to Cite?
AbstractHigh intensive focused ultrasound ablation (HIFU) is a novo noninvasive ablation methods for hepatocellular carcinoma (HCC). Emerging evidence has shown that it is effective in the treatment of HCC particularly in patient with poor liver function. Unlike partial hepatectomy or RFA for HCC on patients with cirrhosis, there are no data on the safety limit of HIFU. However, information is vital for the selection of appropriate patients for the procedure. In this study, we analyzed the results of HIFU on HCC patients and determined the lower limit of liver function and other patient’s factors with which HCC patients can tolerate HIFU. METHOD: Preoperative variables of consecutive 100 patients who underwent HIFU for HCC were analyzed to identify the risk factors in HIFU intolerance in terms of morbidity associated with stress-induced complications. RESULTS: 15 patients were in Child Pugh grade B liver cirrhosis and 1 patient was in Pugh Child C liver cirrhosis. 15 patients presented with ascites before treatment. Thirteen (13%) patients developed intolerance to HIFU. Postoperative morbidity was mainly due to skin and subcutaneous injury (n = 9), five patients developed first degree skin burn, one patient developed second degree skin burn and three patients developed third degree skin burn. Two patients developed pneumothorax, one patient developed hyperbilirubinemia and six patients developed other complications. Univariated analysis only showed that age (p = 0.022) is the single independent factor that predict the development of intolerance. CONCLUSIONS: HIFU is generally well tolerated inpatients with cirrhosis. This is a safe method for patients even when TACE is considered risky as a treatment modality. This ablative treatment modality can be used in selected patients with Pugh Child C liver cirrhosis.
Descriptionpp. 3-558 of this journal issue contain Abstracts of the 21st APASL Conference 2011
Persistent Identifierhttp://hdl.handle.net/10722/136096
ISSN
2014 Impact Factor: 1.780
2014 SCImago Journal Rankings: 0.609
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorCheung, TTen_US
dc.contributor.authorPoon, RTPen_US
dc.contributor.authorLo, CMen_US
dc.contributor.authorFan, STen_US
dc.date.accessioned2011-07-27T02:02:45Z-
dc.date.available2011-07-27T02:02:45Z-
dc.date.issued2011en_US
dc.identifier.citationThe 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 453-454, abstract PP33-13en_US
dc.identifier.issn1936-0533-
dc.identifier.urihttp://hdl.handle.net/10722/136096-
dc.descriptionpp. 3-558 of this journal issue contain Abstracts of the 21st APASL Conference 2011-
dc.description.abstractHigh intensive focused ultrasound ablation (HIFU) is a novo noninvasive ablation methods for hepatocellular carcinoma (HCC). Emerging evidence has shown that it is effective in the treatment of HCC particularly in patient with poor liver function. Unlike partial hepatectomy or RFA for HCC on patients with cirrhosis, there are no data on the safety limit of HIFU. However, information is vital for the selection of appropriate patients for the procedure. In this study, we analyzed the results of HIFU on HCC patients and determined the lower limit of liver function and other patient’s factors with which HCC patients can tolerate HIFU. METHOD: Preoperative variables of consecutive 100 patients who underwent HIFU for HCC were analyzed to identify the risk factors in HIFU intolerance in terms of morbidity associated with stress-induced complications. RESULTS: 15 patients were in Child Pugh grade B liver cirrhosis and 1 patient was in Pugh Child C liver cirrhosis. 15 patients presented with ascites before treatment. Thirteen (13%) patients developed intolerance to HIFU. Postoperative morbidity was mainly due to skin and subcutaneous injury (n = 9), five patients developed first degree skin burn, one patient developed second degree skin burn and three patients developed third degree skin burn. Two patients developed pneumothorax, one patient developed hyperbilirubinemia and six patients developed other complications. Univariated analysis only showed that age (p = 0.022) is the single independent factor that predict the development of intolerance. CONCLUSIONS: HIFU is generally well tolerated inpatients with cirrhosis. This is a safe method for patients even when TACE is considered risky as a treatment modality. This ablative treatment modality can be used in selected patients with Pugh Child C liver cirrhosis.-
dc.languageengen_US
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0-
dc.relation.ispartofHepatology Internationalen_US
dc.rightsThe original publication is available at www.springerlink.com-
dc.subjectMedical sciences-
dc.subjectEndocrinology-
dc.titleSafety and tolerance of high intensive focused ultrasound ablation for hepatocellular carcinoma in 100 consecutive patientsen_US
dc.typeConference_Paperen_US
dc.identifier.emailCheung, TT: cheung68@hku.hken_US
dc.identifier.emailPoon, RTP: poontp@hku.hken_US
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_US
dc.identifier.emailFan, ST: stfan@hku.hken_US
dc.identifier.authorityPoon, RTP=rp00446en_US
dc.identifier.authorityLo, CM=rp00412en_US
dc.identifier.authorityFan, ST=rp00355en_US
dc.identifier.doi10.1007/s12072-010-9241-z-
dc.identifier.hkuros188342en_US
dc.identifier.volume5en_US
dc.identifier.issue1-
dc.identifier.spage453en_US
dc.identifier.epage454en_US
dc.identifier.isiWOS:000300105300001-
dc.publisher.placeUnited States-
dc.description.otherThe 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 453-454, abstract PP33-13-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats